• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

品牌利培酮与类似利培酮治疗老年神经精神障碍患者的疗效及安全性：一项回顾性研究。

Efficacy and safety of brand-risperidone versus similar-risperidone in elderly patients with neuropsychiatric disorders: A retrospective study.

作者信息

Folquitto Jefferson Cunha, de Barros Sérgio Barbosa, Pinto Junior Jony Arrais, Bottino Cássio M C

机构信息

Projeto Terceira Idade (PROTER), Instituto e Departamento de Psiquiatria, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brasil.

Departamento de Estatística, Universidade de São Paulo, São Paulo, Brasil, Projeto Terceira Idade (PROTER), Instituto e Departamento de Psiquiatria, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brasil.

出版信息

Dement Neuropsychol. 2010 Jan-Mar;4(1):69-74. doi: 10.1590/S1980-57642010DN40100012.

DOI:10.1590/S1980-57642010DN40100012
PMID:29213664
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5619534/
Abstract

UNLABELLED

To compare the efficacy and tolerability of brand-risperidone against similar-risperidone in elderly outpatients.

METHOD

The medical files of 16 elderly outpatients from the IPq-HCFMUSP treated with two formulations of risperidone (brand and similar) between July/1999 and February/2000 were reviewed. Two independent raters, using the Clinical Global Impression scale, evaluated the efficacy of the treatment with risperidone and the frequency of adverse effects.

RESULTS

Comparing October/1999 to November/1999, Rater 1 observed a trend (p=0.059) and Rater 2 found a statistically significant difference, in favor of the brand-risperidone group (p=0.014). Comparing October/1999 to February/2000, Rater 1 observed no statistically significant difference (p=0.190), but the Rater 2 found a statistically significant difference in favor of the brand-risperidone group (p=0.029). Comparing November/1999 to February/2000, both raters found no statistically significant differences between both risperidone formulations. Regarding adverse effects, a statistically significant difference (p=0.046) was found in favor of the patients treated with brand-risperidone.

CONCLUSIONS

The risperidone-reference, compared to similar-risperidone, showed a trend toward greater efficacy and tolerability.

摘要

未标注

比较品牌利培酮与类似利培酮在老年门诊患者中的疗效和耐受性。

方法

回顾了1999年7月至2000年2月期间在IPq-HCFMUSP接受两种利培酮制剂（品牌和类似制剂）治疗的16名老年门诊患者的病历。两名独立评估者使用临床总体印象量表评估利培酮治疗的疗效和不良反应的发生频率。

结果

将1999年10月与1999年11月进行比较，评估者1观察到一种趋势（p=0.059），评估者2发现存在统计学显著差异，支持品牌利培酮组（p=0.014）。将1999年10月与2000年2月进行比较，评估者1未观察到统计学显著差异（p=0.190），但评估者2发现存在统计学显著差异，支持品牌利培酮组（p=0.029）。将1999年11月与2000年2月进行比较，两名评估者均未发现两种利培酮制剂之间存在统计学显著差异。关于不良反应，发现存在统计学显著差异（p=0.046），支持接受品牌利培酮治疗的患者。

结论

与类似利培酮相比，参比利培酮显示出疗效和耐受性更佳的趋势。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e077/5619534/717c95352c87/dn-04-01-0069-g01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e077/5619534/717c95352c87/dn-04-01-0069-g01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e077/5619534/717c95352c87/dn-04-01-0069-g01.jpg

相似文献

1
Efficacy and safety of brand-risperidone versus similar-risperidone in elderly patients with neuropsychiatric disorders: A retrospective study.品牌利培酮与类似利培酮治疗老年神经精神障碍患者的疗效及安全性：一项回顾性研究。
Dement Neuropsychol. 2010 Jan-Mar;4(1):69-74. doi: 10.1590/S1980-57642010DN40100012.
2
Quetiapine versus risperidone in elderly patients with behavioural and psychological symptoms of dementia: efficacy, safety and cognitive function.喹硫平与利培酮治疗老年痴呆行为和心理症状的疗效、安全性及认知功能比较
Eur Psychiatry. 2007 Sep;22(6):395-403. doi: 10.1016/j.eurpsy.2007.03.001. Epub 2007 May 4.
3
A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: the quetiapine experience with safety and tolerability (QUEST) study.喹硫平与利培酮治疗精神分裂症及其他精神障碍门诊患者的相对安全性、疗效和耐受性比较：喹硫平安全性与耐受性研究（QUEST）
Clin Ther. 2001 Nov;23(11):1839-54. doi: 10.1016/s0149-2918(00)89080-3.
4
A Comparative Study of Short Term Efficacy of Aripiprazole and Risperidone in Schizophrenia.阿立哌唑与利培酮治疗精神分裂症的短期疗效比较研究。
Curr Neuropharmacol. 2017 Nov 14;15(8):1073-1084. doi: 10.2174/1570159X15666170113100611.
5
A randomized, 1-year follow-up study of olanzapine and risperidone in the treatment of negative symptoms in outpatients with schizophrenia.奥氮平与利培酮治疗精神分裂症门诊患者阴性症状的随机、1年随访研究。
J Clin Psychopharmacol. 2006 Jun;26(3):238-49. doi: 10.1097/01.jcp.0000222513.63767.de.
6
Switching patients with stable schizophrenia or schizoaffective disorder from olanzapine to risperidone long-acting injectable.将稳定期精神分裂症或分裂情感性障碍患者由奥氮平转换为利培酮长效注射剂。
Clin Drug Investig. 2012 Apr 1;32(4):267-79. doi: 10.2165/11599080-000000000-00000.
7
Efficacy and tolerability of risperidone, yokukansan, and fluvoxamine for the treatment of behavioral and psychological symptoms of dementia: a blinded, randomized trial.利培酮、和汉方及氟伏沙明治疗痴呆患者行为和心理症状的疗效和耐受性：一项盲法、随机试验。
J Clin Psychopharmacol. 2013 Oct;33(5):600-7. doi: 10.1097/JCP.0b013e31829798d5.
8
Management of agitation, aggression, and psychosis associated with dementia: a pooled analysis including three randomized, placebo-controlled double-blind trials in nursing home residents treated with risperidone.与痴呆相关的激越、攻击行为和精神病的管理：一项汇总分析，包括三项在接受利培酮治疗的疗养院居民中进行的随机、安慰剂对照双盲试验。
Clin Neurol Neurosurg. 2005 Oct;107(6):497-508. doi: 10.1016/j.clineuro.2005.03.013.
9
[Safety and tolerability of olanzapine versus risperidone: a one-year randomized study in outpatients with schizophrenia with prominent negative symptoms].奥氮平与利培酮的安全性和耐受性：一项针对伴有明显阴性症状的精神分裂症门诊患者的为期一年的随机研究
Actas Esp Psiquiatr. 2007 Mar-Apr;35(2):105-14.
10
A comparison of ziprasidone and risperidone in the long-term treatment of schizophrenia: a 44-week, double-blind, continuation study.齐拉西酮与利培酮长期治疗精神分裂症的比较：一项44周双盲延续性研究。
Can J Psychiatry. 2009 Jan;54(1):46-54. doi: 10.1177/070674370905400108.

本文引用的文献

1
Lack of bioequivalence between generic risperidone oral solution and originator risperidone tablets.仿制利培酮口服溶液与原研利培酮片剂之间缺乏生物等效性。
Int J Clin Pharmacol Ther. 2007 May;45(5):293-9. doi: 10.5414/cpp45293.
2
Atypical antipsychotics in the treatment of mania: a meta-analysis of randomized, placebo-controlled trials.非典型抗精神病药物治疗躁狂症：随机安慰剂对照试验的荟萃分析。
J Clin Psychiatry. 2006 Apr;67(4):509-16. doi: 10.4088/jcp.v67n0401.
3
[Treatment of non cognitive symptoms of Alzheimer's disease].[阿尔茨海默病非认知症状的治疗]
Rev Neurol. 2006;42(8):482-8.
4
The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease.非典型抗精神病药物治疗阿尔茨海默病攻击行为和精神病的有效性。
Cochrane Database Syst Rev. 2006 Jan 25;2006(1):CD003476. doi: 10.1002/14651858.CD003476.pub2.
5
Using antipsychotic agents in older patients.在老年患者中使用抗精神病药物。
J Clin Psychiatry. 2004;65 Suppl 2:5-99; discussion 100-102; quiz 103-4.
6
[Comparative bioavailability study of two formulations of risperidone available in the Chilean market].[智利市场上两种利培酮制剂的生物利用度对比研究]
Rev Med Chil. 2003 May;131(5):527-34.
7
The bioequivalence and therapeutic efficacy of generic versus brand-name psychoactive drugs.通用型与品牌型精神活性药物的生物等效性及治疗效果。
Clin Ther. 2003 Jun;25(6):1578-92. doi: 10.1016/s0149-2918(03)80157-1.
8
Risperidone versus typical antipsychotic medication for schizophrenia.利培酮与传统抗精神病药物治疗精神分裂症的比较。
Cochrane Database Syst Rev. 2003(2):CD000440. doi: 10.1002/14651858.CD000440.
9
A meta-analysis of the efficacy of second-generation antipsychotics.第二代抗精神病药物疗效的荟萃分析。
Arch Gen Psychiatry. 2003 Jun;60(6):553-64. doi: 10.1001/archpsyc.60.6.553.
10
A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia.一项关于利培酮治疗痴呆症攻击行为、激越和精神病的随机安慰剂对照试验。
J Clin Psychiatry. 2003 Feb;64(2):134-43. doi: 10.4088/jcp.v64n0205.